稳健医疗(300888) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥1,760,074,735.66, a decrease of 67.06% year-on-year, primarily due to exceptionally high export revenue from medical consumables in Q3 2020[4] - Net profit attributable to shareholders for Q3 2021 was ¥343,002,814.94, down 83.80% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥321,472,260.73, reflecting an 84.76% decrease year-on-year[4] - Basic earnings per share for Q3 2021 were ¥0.80, down 85.79% year-on-year[4] - Total operating revenue for Q3 2021 was CNY 5,819,940,390.58, a decrease of 38.5% compared to CNY 9,523,149,008.70 in the same period last year[29] - Net profit for Q3 2021 reached CNY 1,104,045,577.95, a decline of 65.1% compared to CNY 3,163,073,572.94 in Q3 2020[30] - Total comprehensive income for Q3 2021 was approximately CNY 1.10 billion, a decrease from CNY 3.16 billion in the same period last year, representing a decline of about 65.2%[31] - Basic earnings per share for Q3 2021 were CNY 2.59, down from CNY 8.37 in Q3 2020, reflecting a decrease of approximately 69.0%[31] Cash Flow and Liquidity - The net cash flow from operating activities for the first three quarters of 2021 decreased by 89.15% to ¥430,363,319.55, mainly due to a reduction in advance payments and increased tax payments[5] - Net cash flow from operating activities for Q3 2021 was CNY 430.36 million, significantly lower than CNY 3.97 billion in Q3 2020, indicating a decline of about 89.2%[34] - Cash inflow from operating activities totaled CNY 6.56 billion in Q3 2021, down from CNY 11.01 billion in the previous year, a decrease of approximately 40.5%[33] - Cash outflow from operating activities was CNY 6.13 billion in Q3 2021, compared to CNY 7.05 billion in Q3 2020, a reduction of about 13.1%[33] - The company reported a net cash outflow from financing activities of CNY 901.96 million in Q3 2021, contrasting with a net inflow of CNY 3.37 billion in Q3 2020[35] - The company's cash and cash equivalents as of September 30, 2021, amounted to approximately 4.43 billion yuan, an increase from 4.16 billion yuan at the end of 2020[24] - Cash and cash equivalents at the end of Q3 2021 stood at CNY 4.40 billion, down from CNY 7.28 billion at the end of Q3 2020, a decrease of approximately 39.5%[35] Assets and Liabilities - Total assets as of September 30, 2021, were ¥13,249,136,580.40, representing a 1.90% increase from the end of the previous year[4] - Total liabilities amounted to CNY 2,550,148,341.11, slightly up from CNY 2,533,861,673.00 in the previous period[27] - The company's equity attributable to shareholders increased by 2.21% to ¥10,684,675,530.88 compared to the end of the previous year[4] - The company's equity attributable to shareholders reached CNY 10,684,675,530.88, compared to CNY 10,453,934,045.43 in the same period last year[27] - Current assets totaled CNY 10,990,095,265.11, with inventory valued at CNY 1,216,486,940.21[38] - Total current liabilities were CNY 2,426,774,803.89, including accounts payable of CNY 726,577,306.94[40] Revenue Segments - The health lifestyle consumer goods segment achieved a revenue of 2.7005 billion yuan in the first three quarters of 2021, representing a year-on-year growth of 16.9% and a 35.8% increase compared to the same period in 2019[19] - The medical consumables segment reported a revenue of 2.8825 billion yuan in the first three quarters of 2021, a decline of 58.4% year-on-year, primarily due to high export sales in the same period last year[20] - The total revenue for the company in the first three quarters of 2021 was 5.7837 billion yuan, down 38.8% compared to the same period in 2020, but up 88.2% compared to 2019[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 34,502, with no preferred shareholders[13] - The largest shareholder, Wanjian Group Co., Ltd., holds 68.10% of the shares, totaling 290,438,848 shares[14] - The company had a total of 379,646,412 shares with restrictions, with 89,207,564 shares released during the period[16] Investment and Dividends - The company distributed dividends and paid interest amounting to ¥568,158,834.96, a significant increase of 459.71% compared to ¥101,509,320.51 in the previous year[12] - Cash received from investment income increased by 872.55% to ¥91,635,280.03, up from ¥9,422,129.63, mainly due to increased returns from financial products[12] - Cash paid for investments rose by 31.26% to ¥4,281,000,000.00 from ¥3,261,480,000.00, attributed to an increase in the purchase of financial products[12] - The company plans to repurchase shares worth 300 million to 500 million yuan, with a maximum repurchase price of 116 yuan per share, aiming to enhance investor confidence and establish a long-term incentive mechanism[21] Social Responsibility - The company donated over 18 million yuan worth of women's and children's products during the Henan flood disaster, demonstrating its commitment to social responsibility[22] Research and Development - Research and development expenses for Q3 2021 were CNY 271,624,601.61, a decrease of 20.6% from CNY 341,983,022.11 in Q3 2020[29] Future Outlook - The company plans to continue focusing on expanding its market presence and investing in new product development to drive future growth[36]